Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
2(5%)
Results Posted
48%(12 trials)
Terminated
2(5%)

Phase Distribution

Ph early_phase_1
1
3%
Ph not_applicable
5
13%
Ph phase_1
8
21%
Ph phase_2
3
8%
Ph phase_4
10
26%
Ph phase_3
10
26%

Phase Distribution

9

Early Stage

3

Mid Stage

20

Late Stage

Phase Distribution37 total trials
Early Phase 1First-in-human
1(2.7%)
Phase 1Safety & dosage
8(21.6%)
Phase 2Efficacy & side effects
3(8.1%)
Phase 3Large-scale testing
10(27.0%)
Phase 4Post-market surveillance
10(27.0%)
N/ANon-phased studies
5(13.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.2%

25 of 29 finished

Non-Completion Rate

13.8%

4 ended early

Currently Active

2

trials recruiting

Total Trials

39

all time

Status Distribution
Active(3)
Completed(25)
Terminated(4)
Other(7)

Detailed Status

Completed25
unknown7
Recruiting2
Terminated2
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
39
Active
2
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.7%)
Phase 18 (21.6%)
Phase 23 (8.1%)
Phase 310 (27.0%)
Phase 410 (27.0%)
N/A5 (13.5%)

Trials by Status

recruiting25%
unknown718%
completed2564%
terminated25%
withdrawn25%
not_yet_recruiting13%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT06929273Phase 3

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Recruiting
NCT05431595Phase 2

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Recruiting
NCT07226141Phase 1

Valproate for the Treatment of Residual Amblyopia

Not Yet Recruiting
NCT06089356Phase 4

Zolmitriptane as Prophylaxis for Chilhood Migraine

Unknown
NCT04513314Phase 4

Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium

Withdrawn
NCT02899611Phase 1

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

Completed
NCT05181007Phase 1

Drug-drug Interaction Between Ciprofol and Mefanamic Acid or Valproate

Completed
NCT00484471Phase 4

ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

Completed
NCT03940326Phase 4

Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

Completed
NCT04191863

Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.

Completed
NCT00167934Not Applicable

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

Completed
NCT03025906Phase 2

Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus

Unknown
NCT01267864Phase 4

Valproate Versus Ketorolac Versus Metoclopramide

Completed
NCT01622439Phase 1

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed
NCT01543139Phase 2

Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression

Withdrawn
NCT00774306Not Applicable

Antiepileptic Drugs and Vascular Risk Markers

Terminated
NCT03235531Phase 4

Assessment of Valproate on Ethanol Withdrawal

Unknown
NCT01463111Not Applicable

Decision-Making in Bipolar Disorder

Completed
NCT02648633Phase 1

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

Terminated
NCT02144623Early Phase 1

Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39